This data sheet provides an overview of Clario’s oncology imaging and endpoint expertise, emphasizing scientific depth, regulatory insight, and operational scalability. It highlights independent, blinded image review performed by board-certified specialists using advanced quantitative and qualitative methodologies. The document outlines capabilities across molecular imaging, tumor response criteria, and a wide range of oncology indications. Clario’s experience spans early-phase studies through large registrational trials, with more than 1,700 oncology trials supported and over 100 regulatory approvals achieved. Additional focus is placed on protocol design consulting, site oversight, compliance with global regulations, and real-time monitoring. The data sheet positions Clario as a comprehe

Join for free to read